

Euphotic

Quantifying Epilepsy

Euphotic is a health technology venture with Finnish roots and global partners. Our mission is to improve the quality of life of patients suffering from neurological diseases, e.g. epilepsy, by providing clinicians with useful tools.

Our goal is to measure cortical excitability noninvasively. We believe this quantification will help clinicians to adjust the dosage of anti-epileptic drugs (AEDs), as well as select the appropriate drug. We expect our product to improve the quality of life of epileptic patients and reduce inpatient days.

The Euphotic method requires an MEG device, novel MEG-compatible Euphotic IPS (Intermittent Photic Stimulation; patent pending) stimulator, and Euphotic IPS data analysis service.

We have started data collection from healthy controls in 2019 and will expand to epileptic patients in 2020.

SPARK VALUE: We expect the SPARK program to aide us in translating our idea into a FDA cleared medical device that customers want to buy. We hope to expand our networks and find partners with experience of medical device business and development

Team

Veikko Jousmäki PhD, Docent, Senior Scientist

Head of Aalto NeuroImaging, Aalto University.

Veikko has 26-years of experience with MEG and in R&D of MEG-compatible stimulators. Veikko has a wide network of international partners including Singapore, USA, Sweden, Belgium and Japan.

Pia Kemppainen-Kajola, M.Sc.

Entrepreneur, Kajola Engineering, Helsinki.

In our project Pia works as a business developer and coordinator.

Jani Issakainen, Student

Physics & Economics student, Research Assistant.

In our project he focuses on developing software, aware of the regulatory conditions for a medical device.